Stifel Initiates Coverage of Roivant Sciences with Buy Rating
Fintel reports that on September 17, 2026, Stifel initiated coverage of Roivant Sciences (NASDAQGS:ROIV) with a Buy recommendation.
Roivant Sciences Ltd., based in Switzerland and the United States, is a biopharmaceutical company that develops medicines via a technology-driven platform and builds 'Vants'—biotech and healthcare technology units—across areas such as neurology, dermatology, and hepatology.
On September 16, 2026, the day prior to the rating action, the stock's pre-action close was $39.57. That close represents a price change of -5.36% over the prior week from a baseline close of $41.81 on September 9, 2026, and a one-month price change of +9.31% from a baseline close of $36.20 on August 14, 2026.
As of September 15, 2026, the current consensus target mean for Roivant Sciences was $46.02, with a median target of $46.92, implying a change of +16.30% from the stock's recent valuation. The prior consensus target mean was $42.26 as of August 28, 2026, representing a consensus target revision of +8.89%.
In the current recommendation period as of September 1, 2026, there were 19 recommendations: 8 strong buy, 9 buy, 2 hold, 0 sell, and 0 strong sell, reflecting a positive recommendation percentage of 89.5% and a hold percentage of 10.5%.
On September 9, 2026, both TD Cowen and Guggenheim maintained their Buy ratings. On September 8, 2026, Jefferies and HC Wainwright & Co. maintained their Buy recommendations.
Roivant Sciences reported its latest quarterly financial results on August 6, 2026. For the quarter, the company reported an actual EPS of -0.26, compared to an estimated EPS of -0.336. Actual revenue was $1,442,000.00, which was below the estimated revenue of $2,097,885.00. According to the company's Form 10-Q filed with the SEC on August 6, 2026, the statement of shareholders' equity recorded a repurchase of the company's common shares of (6,892,463) shares, representing (208,703). Additionally, in an EX-99.1 filing dated August 6, 2026, titled "Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update," the company stated that commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026, with topline data from the Phase 3 study in non-infectious uveitis (NIU) expected in the second half of calendar year 2026.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 17, 2026 | Stifel | Buy | initiated coverage | |
| September 9, 2026 | TD Cowen | Buy | Buy | maintained |
| September 9, 2026 | Guggenheim | Buy | Buy | maintained |
| September 8, 2026 | Jefferies | Buy | Buy | maintained |
| September 8, 2026 | HC Wainwright & Co. | Buy | Buy | maintained |
| August 28, 2026 | HC Wainwright & Co. | Buy | Buy | reiterated |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.